Literature DB >> 28228485

Probability of vertical transmission of Chlamydia trachomatis estimated from national registry data.

Minna Honkila1,2, Erika Wikström2, Marjo Renko1,2, Heljä-Marja Surcel3, Tytti Pokka1,2, Irma Ikäheimo4, Matti Uhari1,2, Terhi Tapiainen1,2.   

Abstract

OBJECTIVES: Chlamydia trachomatis colonisation is common in pregnant women, and it has been claimed that mother-to-child transmission may occur in 10%-70% of deliveries. C. trachomatis infections are nevertheless rarely encountered in infants in clinical practice. In order to evaluate the reason for this discrepancy, we designed a nationwide study of the C. trachomatis vertical transmission.
METHODS: Children with a possible C. trachomatis infection were identified from two national health registries in 1996-2011. Copies of the children's medical records were reviewed and maternal serum bank samples obtained during the index pregnancies were analysed for C. trachomatis antibodies. The risk of vertical transmission was calculated using data from two earlier studies in which nucleic acid amplification test (NAAT) positivity and seroconversion rates among women in the general population were reported.
RESULTS: Altogether 206 children had a possible C. trachomatis infection, which represents 0.22 per 1000 live births (95% CI 0.19 to 0.25). The risk of vertical transmission among the estimated 24 901 NAAT-positive mothers was 0.8% (95% CI 0.7 to 0.9). Based on the annual seroconversion rate of maternal antitrachomatis antibodies, the risk of vertical transmission was 1.8% (95% CI 1.5 to 2.0). Altogether 35% of the maternal serum samples obtained in the first trimester of a pregnancy leading to a C. trachomatis infection in the infant were negative, implying that the infection was acquired during pregnancy.
CONCLUSIONS: C. trachomatis infections in infants were rare, with a population-based occurrence of 0.22 per 1000 live births. The risk of vertical transmission of C. trachomatis in the population was <2%, which is significantly lower than reported earlier. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  CHILDREN; CHLAMYDIA TRACHOMATIS; EPIDEMIOLOGY (CLINICAL); SEROLOGY

Mesh:

Year:  2017        PMID: 28228485     DOI: 10.1136/sextrans-2016-052884

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  5 in total

1.  Influence of different delivery modes on the clinical characteristics of Chlamydia trachomatis pneumonia.

Authors:  Jiejing Xu; Lili Yu; Baidi Fu; Deyu Zhao; Feng Liu
Journal:  Eur J Pediatr       Date:  2018-05-31       Impact factor: 3.183

Review 2.  Advancing the public health applications of Chlamydia trachomatis serology.

Authors:  Sarah C Woodhall; Rachel J Gorwitz; Stephanie J Migchelsen; Sami L Gottlieb; Patrick J Horner; William M Geisler; Catherine Winstanley; Katrin Hufnagel; Tim Waterboer; Diana L Martin; Wilhelmina M Huston; Charlotte A Gaydos; Carolyn Deal; Magnus Unemo; J Kevin Dunbar; Kyle Bernstein
Journal:  Lancet Infect Dis       Date:  2018-07-05       Impact factor: 25.071

3.  Significant Associations between Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Human Immunodeficiency Virus-Infected Pregnant Women.

Authors:  Bongekile Ngobese; Khine Swe Swe-Han; Partson Tinarwo; Nathlee S Abbai
Journal:  Infect Dis Obstet Gynecol       Date:  2022-06-17

4.  Detection of Neisseria gonorrhoeae and Chlamydia trachomatis infections in pregnant women by multiplex recombinase polymerase amplification.

Authors:  Jingjing Zhai; Limin Wang; Xiaoliang Qiao; Jianping Zhao; Xuexia Wang; Xiaohong He
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.752

5.  Aetiology of neonatal conjunctivitis evaluated in a population-based setting.

Authors:  Minna Honkila; Marjo Renko; Irma Ikäheimo; Tytti Pokka; Matti Uhari; Terhi Tapiainen
Journal:  Acta Paediatr       Date:  2018-02-06       Impact factor: 2.299

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.